Stem cell committee urged to slow down
By Terri Somers,
San Diego Union-Tribune
| 01. 07. 2005
Ethics rules, transparency discussed at 2nd meeting
The committee that will dole out $3 billion in state grants for stem cell research heard yesterday from critics and some of its own members who said the group should slow down in its race to get money to scientists.
As the committee met for the second time, one of the overriding messages from the public and some of the committee members was to start by establishing standards for complicated and weighty issues such as how to reimburse taxpayers for their investment.
"No one wants results to come back faster than I do," said committee member Joan Samuelson, a former lawyer who has Parkinson's disease. "But some of these questions and issues are complicated. Some of the answers may take awhile."
The stem cell initiative that voters approved in November was set up to sidestep the slow crawl of bureaucracy and quickly get money to scientists looking for cures to diseases such as Parkinson's and Lou Gehrig's.
The committee's goal is to write the first check by the end of May, said Robert...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
